

A Display of Confidence in Xenia

The Yalin Lapidot Investment House Invests in Xenia

Anat Segal: "We are happy with the decision of the esteemed Yalin Lapidot investment house to join our distinguished list of institutional stakeholders."

Israel, Herzliya, November 7, 2013, Xenia Venture Capital (TASE:XENA), announced that the Yalin Lapidot investment house has become a stakeholder in the company. Xenia has several portfolio companies which have cumulatively raised tens of millions of shekels this year.

The following are Xenia's most mature companies:

Superfish has been focusing on developing visual search technologies, and in 2011 launched its WindowShopper platform, which is based on a technology designed to improve the online shopping experience. Today WindowShopper is used by tens of millions of users with thousands of searches taking place every second. Now that it has proven its ability to ensure the mass-scale use of its technology and to provide added value for its users, Superfish intends to launch visual search solutions in social network and mobile device environments as well, and also seeks to make the technology available to third parties.

Playcast has developed a video server which allows for the compression and transmission of high quality video games. Playcast's server enables cable and telecom service providers to offer their customers AAA grade gaming services, with the quality of online games and gaming consoles. This technology requires no change in the existing consumer side set top boxes or network infrastructure. Playcast's technology enables service providers to increase their ARPU without further infrastructure investments. Playcast was founded in 2007 by Guy De Beer, a former senior manager at Harmonic. Its investors include JVP, MK Capital and Xenia Venture Capital.

Ortho-Space has begun sales, both in Europe and Israel, of a balloon which is intended to treat patients suffering from shoulder pain as a result of the Rotator Cuff Syndrome. The treatment offers a unique, one of a kind, solution to patients suffering from this syndrome, which causes pain and severe movement restriction in the shoulder joint, except for the suturing of tendons -- a surgical procedure which is performed in severe cases necessitating surgical intervention. Ortho-Space's solution, as opposed to surgery, is performed as a minimally invasive procedure, in clinics, and does not entail hospitalization or a prolonged period of recovery, as in cases of surgical procedures, resulting in immediate and significant improvement in range of movement and immediate pain relief.

PolyPid has developed a unique drug carrier technology that enables long lasting and pre-programmed release of a wide range of therapeutic drugs. PolyPid's technology can serve as a platform for a large number of applications which will enable more efficient treatment of long term local treatment required in many medical fields. PolyPid currently develops a family of products aimed at the treatment of bone infections in the field of orthopedics. PolyPid's solution constitutes a unique platform combining the prompting of bone regeneration by using biological scaffolding, which is currently used in this field, and local,

effective antibiotic treatment, which is already activated at the preliminary surgical procedure stage. PolyPid's board of directors and its advisory board include key names from the local and international world of therapeutic drugs, including Dr. Yafit Stark, Chief Clinical Officer at Teva Pharmaceutical industries Ltd and member of Xenia's advisory board, Prof. Hezi Bernholtz, Prof. David Segal and others.

Medi-Tate develops products designed to treat urethral and prostate conditions, its flagship product being designed for treating patients with benign prostate hyperplasia (BPH). The company has obtained CE marking for marketing the device in Europe. In the United States alone there are approx. 15 million men suffering from benign prostate hyperplasia. Only about 3 million of them are treated, 90% with medications and 10% through surgical intervention. In the United States this market is estimated at USD 3 billion, while in the rest of the world more than 500,000 procedures are carried out every year.

About Xenia Venture Capital:

Xenia Venture Capital is a publically traded investment company which operates a privatized technology incubator that invests in seed stage start ups and initiatives in the fields of medical devices and IT. Among Xenia's founders and main shareholders are the Novacom Group and C. Mer Industries, leading institutional investors such as IBI, Menora Insurance Group, Dash Apax, Mivne Taasia (of the Fishman Group), Anat Segal (CEO), as well as additional hi tech and industry figures. Xenia's Board of Directors and Advisory Board comprises highly successful entrepreneurs and high-tech industry executives, including Haim Mer, Tal Menipaz (Chairman of the Board), Prof. Gaby Barabash, Dr. Yafit Stark, Prof. Yossi Shacham, and others. The aim of the company is to jump-start and accompany start up companies in the field of technology and medical devices, striving to increase the companies' chances to succeed and realize their business potential. Since its inception, Xenia has invested in dozens of companies, many of which have completed follow-on investment rounds, launched products in global markets, reached significant sales and profitability, and formed valuable strategic partnerships.

Please visit our website at: www.xenia.co.il